Printer Friendly Version View printer-friendly version
<< Back
Incyte Announces Oncology Research Alliance with the Abramson Cancer Center at the University of Pennsylvania

Collaboration aims to advance the understanding of cancer biology and foster innovative science in immunotherapy

WILMINGTON, Del.--(BUSINESS WIRE)--Feb. 23, 2017-- Incyte Corporation (Nasdaq:INCY) today announces a multi-year research collaboration with the Abramson Cancer Center at the University of Pennsylvania. Through this collaboration, Incyte and Abramson have agreed to bring together the knowledge and expertise of their leading drug discovery and development scientists to conduct collaborative research aimed at advancing the understanding of cancer biology and fostering innovative science in immunotherapy.

Under the collaboration, Penn investigators will leverage their expertise in preclinical biology and translational science to investigate the novel therapeutics being discovered at Incyte and better understand their mechanisms of action—further developing the clinical rationales for combination therapy and patient selection. Additionally, in a combined effort to better define the relationships between human tumor characteristics and immune cell infiltration and function, Incyte and Penn will work together to develop a bioinformatics program in clinical immunotherapy aimed at fostering the advancement of novel therapeutics.

During the period of the collaboration, Incyte will provide financial support for these research programs and may also conduct additional grant-funded research with Penn investigators in other innovative areas of cancer immunology.

“Incyte and Abramson are mutually committed to the advancement of science and improving the lives of patients with cancer. This alliance will allow us to mobilize two groups of leading scientists toward the collective goal of advancing the field of immunotherapy,” said Reid Huber, Ph.D., Chief Scientific Officer at Incyte. “We are excited for the opportunity to partner with the world-class researchers at Abramson and investigate new avenues for the treatment of patients with cancer.”

About Incyte

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at

Follow @Incyte on Twitter at

Incyte Forward-Looking Statements

Except for the historical information set forth herein, the matters set forth in this press release – including statements regarding the Company’s collaboration with the Abramson Cancer Center at the University of Pennsylvania and whether it will advance the understanding of cancer biology or foster innovative science in immunotherapy - contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its Form 10-K for the year ending December 31, 2016. Incyte disclaims any intent or obligation to update these forward-looking statements.

Source: Incyte Corporation

Incyte Corporation
Catalina Loveman, +1 302-498-6171
Michael Booth, DPhil, +1 302-498-5914

RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet